Adrian O'Dowd margaTe
The government is to review a longstanding rule that forbids NHS patients in England from topping up their treatment by buying drugs that are not available on the NHS.
The Department of Health is signalling that it may consider changing the rule on such copayments. Currently anyone who buys their own drugs has to become a private patient and thus pay for the whole of their care themselves.
Pressure has been building for a change after cases in which patients in the final stages of cancer wanted to pay for drugs that were new and had not yet been approved for use in the NHS by the National Institute for Health and Clinical Excellence or had been rejected for reasons of cost or effectiveness.
In one case Linda O'Boyle, from Essex, was refused further NHS treatment for bowel cancer after she paid £11 000 (€14 000; $22 000) for cetuximab. She died in March, and since then other patients have threatened legal action over the refusal of the NHS to allow copayment. The health secretary, Alan Johnson, told MPs in the House of Commons last week that he had asked Mike Richards, the national director for cancer, to look into the "very complex" issues raised by copayments and report back by October.
The government has argued previously that allowing copayments would create a two tier service in the NHS, going against its founding principles. The rules apply across the UK health services, and the administrations in Wales and Northern Ireland have said they will watch the review closely, while Scotland has launched a similar review, although looking only at drugs for cancer.
Doctors at the BMA's annual conference for consultants earlier this month voted for an end to the policy banning copayments, but this is not yet official policy until it is voted on at next month's full annual conference of the BMA.
Niall Dickson, chief executive of the healthcare think tank the King's Fund, said, "The challenge is to protect the overall integrity of our current funding system, while seeing whether there are ways of accommodating a small number of patients in extreme cases to top up their care.
The NHS Confederation, which represents most NHS organisations, said that the rule had to change.
More than one in five patients in England and
Wales who have acute myocardial infarction are receiving angioplasty as their first line of treatment (primary angioplasty), the latest figures from the myocardial ischaemia national audit project show.
But "effective communication" between referring hospitals, ambulance services, hospitals doing the angioplasty, and primary care is needed for further improvement to be made, its authors say.
The audit, now in its seventh year, measures how quickly hospitals and ambulance services have carried out primary angioplasty or thrombolytic treatment in patients who have had a heart attack.
A call in 2006 by Roger Boyle, the national clinical director for heart disease and stroke, to prioritise angioplasty has led to more trusts using it, particularly in some areas, such as London and Birmingham and the Black Country, the audit shows.
In England, the results for 2007-8 show that 54 hospitals carried out angioplasty instead of giving the patients thrombolytics, whereas the year before the number was 35. This meant that 4472 patients were treated with primary angioplasty in 2007-8, a rise of 42% on the 2006-7 figure of 3148.
However, 17 hospitals performed fewer than 10 angioplasties, and seven of the 30 English cardiac networks reported that they had restricted access to primary angioplasty services. Many are only now starting primary angioplasty programmes, and services are offered only during business hours, the audit said. Others perform angioplasty only when thrombolysis is contraindicated. In Wales, the situation was worse, with only two hospitals performing primary angioplasty.
Angioplasty and thrombolysis are both most effective when carried out within three hours of the onset of symptoms. The audit found that more than 60% of patients were treated in this time, with 79% of patients in England receiving angioplasty within 90 minutes of arrival at hospital.
The speed of administering thrombolytic treatment has risen, with more paramedic teams being trained in the procedure. Nearly three quarters (71%) of patients received thrombolytic treatment within 60 minutes of a phone call in England, up from 64% the year before. In Wales the figure rose from 42% in 2006-7 to 49%. Greater numbers of trusts in both countries are also providing thrombolytic treatment to three quarters of eligible patients within 30 minutes of arrival at hospital: 90% this year in England (81% in 2006-7) and 36% in Wales (33%).
See www.rcplondon.ac.uk/college/ceeu/ceeu_ ami_home.htm for more information.
Choice of cancer vaccine is branded a
Zosia Kmietowicz London Girls throughout the United Kingdom will receive the human papillomavirus vaccine Cervarix in the national immunisation programme after it launches in September, the Department of Health has said.
Cervarix, which is made by GlaxoSmithKline, offers protection against human papillomavirus types 16 and 18, which are responsible for about 70% of cervical cancers. In England, 300 000 girls aged 12 to 13 will be given the vaccine in the first year of the programme. In the next two years 1.8 million doses of vaccine will be dispensed for routine and catch-up vaccinations for girls aged 14 to 18. Dawn Primarolo, the health minister, described the vaccine as "an exciting opportunity" that could save the lives of 400 women a year.
However Noting that Dr Persaud had cut down on his media work, Dr Morgan said the panel believed that he was unlikely to repeat his actions in the future. The panel, he said, "has had regard to the fact that there has been no patient harm."
A three month suspension, he concluded, "is sufficient to send out a signal to you, the profession, and the public that plagiarism is unacceptable behaviour."
The original complainant to the GMC was a US pressure group, the Citizens Commission on Human Rights, which was founded by the Church of Scientology to "investigate and expose psychiatric violations of human rights." Scientologist doctrine holds that psychiatry is a fraud. Dr Persaud criticised the church's founder, L Ron Hubbard, in a 2005 article in the Independent newspaper entitled "A dangerous war on psychiatry." Part of this article was later found to have been plagiarised.
missed opportunity by charities GMC panel chairman said Raj Persaud was unlikely to offend again
Joyce Gould, chairwoman of the Independent Advisory Group on Sexual Health and HIV, which monitors the progress of the government's strategy for sexual health, described the new programme as "an extraordinary breakthrough for women in this country."
However, Baroness Gould added that it was important to review the effectiveness and benefits of both vaccines. "We would also welcome more clarity as to why Cervarix was selected above Gardasil, given [that] protection against genital warts seems a very important benefit for women as well," she said.
While welcoming the programme, Julie Bentley, chief executive of the Family Planning Association, said, "Selecting the Gardasil vaccine would have been a huge preventive measure in terms of health and financial costs to the NHS. Genital warts is the second most common sexually transmitted infection in the UK after chlamydia."
The health department would not disclose details of its deal with GlaxoSmithKline to supply the vaccine.
A spokesman for GlaxoSmithKline said that it was unsurprising that Gardasil had won more contracts than its own drug, as Gardasil was licensed a year earlier. 
NEWS Rebecca Coombes London
The United Kingdom has little choice but to pull more private funds into the NHS, by such methods as allowing patients to top up care by paying out of their own pocket, if it is to maintain and improve healthcare standards in the future, a leading academic said this week. Chris Ham, professor of health policy and management at Birmingham University, who was giving the first BMJ lecture, pointed out that the UK relied far less on private funding than other Organisation for Economic Cooperation and Development (OECD) countries. In the UK, 87% of health spending comes from the public purse, compared with 72-73% in the average OECD country.
"If we look at our funding levels in the UK compared to OECD countries, we are now at one end of the spectrum. If we are going to fund new technologies, how far are we willing to move in the direction of other OECD countries?" He said it was almost a foregone conclusion that the government will allow cancer patients to make "top up" payments for drugs not yet approved by the National Institute for Health and Clinical Excellence without jeopardising their right to free NHS care. National director of cancer services Mike Richards is currently reviewing the issue.
Chris Ham said: "It is self evident the government cannot take a hard line on this. My suspicion is that Mike Richards already rex NHS must attract more private money if it is to improve knows the answer." He said the issue of payment on cancer drugs was a "straw in the wind" to the much bigger challenge "of how the private and public mix of funding will shift over time."
Chris Ham told the BMJ after the lecture that he expected to see more "out of pocket payments" in the form of paying for top-up care. "Or the government might introduce more charges for NHS services, such as visiting the GP, attending outpatients, or an overnight stay in hospital. More people might choose to take out private medical insurance, or a future government, such as the Conservatives, may give people tax breaks in order to fund private medical insurance." "In the past six to seven years the NHS has been the biggest beneficiary of increased public funding, but that is unlikely to go on. But what is coming through the pipeline? Where are the other ways of levering raw resources in? There is no advantage to us shifting away from tax funding. Social insurance models are in a worse shape than we are. So it has to be private funding. But none of the political parties are leading a debate around that." Professor Ham's lecture looked at what doctors could expect from the final report of health minister Ara Darzi's review of the NHS, due to be published on 30 June. The professor expected the report to feature new pilots of "integrated care schemes," where budgets are devolved from primary care trusts to provider organisations, including GP practice based commissioning consortiums.
The consortiums would be free to decide on whether to provide more services themselves or to contract community nurses and therapists, or local hospitals.
Psychiatrist is suspended for three months for plagiarism
found that one of the products, known as Vita-Cell, contained a substance that may have required registration with the MCC and that this had not been done.
And neither had investigations been adequately carried out once complaints were laid, he found. Vita-Cell had been "donated" to various clinics in deprived areas through a civic organisation known as Sanco.
One of the more politically contentious areas of the judgment dealt with the request of the action campaign and the medical association that the health minister, her staff, and the MCC head and its staff be ordered to do their jobs properly in investigating drugs and their sale. The judge decided that these tasks had not been adequately carried out, and he ordered the minister to undertake her duty in this regard.
The order referring to Dr TshabalalaMsimang and her director general said that they were "under a duty to take reasonable measures to prevent [ (MCC) . At the same time it has ordered the health minister to do her job properly in ensuring that treatments requiring registration are properly scrutinised.
The medical association and the action campaign had asked the court for an interdict that would stop Dr Rath, the South African government, the health minister, her director general, the top officials dealing with drug registration through the MCC, and several well known campaigners who claim that HIV is not the cause of AIDS from conducting clinical trials on patients with AIDS or selling and advertising Dr Rath's products.
The judge found that unauthorised clinical trials had taken place and had to be stopped. He also
Judge orders South African health minister to do her job properly Peter Moszynski london
Suspected terrorists held at US detention facilities were "systematically subjected to torture and ill treatment," says a detailed medical and psychological evaluation of former detainees conducted by Physicians for Human Rights.
The findings were announced last week at a press conference at the BMA, where investigators from the organisation described how they uncovered "medical evidence of torture and ill treatment inflicted on 11 men detained at US facilities in Iraq, Afghanistan, and Guantánamo Bay who were never charged with any crime."
Their investigations detail the "severe physical and psychological pain and longterm disability that has resulted from abusive and unlawful US interrogation practices." In the report Major General Antonio Taguba, who led the US Army's investigation into the abuse scandal at Abu Ghraib detention centre, points out that "the healing professions, including physicians and psychologists, became complicit in the wilful infliction of harm against those the Hippocratic Oath demands they protect."
Complaining that the UN Convention against Torture was ignored, General Taguba says: "There is no longer any doubt as to whether the current administration has committed war crimes. The only question is In Nepal the number of maternal deaths fell by almost 50% in 10 years, from 539 per 100 000 live births in 1996 to 281 in 2006. However, another more recent analysis indicates that the fall in maternal mortality was about 20% over the past 10 years. During the same period in Nepal the percentage of deliveries with a skilled birth attendant, midwife, or doctor present rose from 9% to 19%, and the birth rate fell from 4.6 births per woman to 3.1. An extra 60 000 women were able to give birth in health facilities in the past year, thanks to a financial voucher scheme set up by the department, says the report.
Despite this progress neither of the countries is likely to meet the target in the United shehzad NooraNi/still pictures UK aid has helped cut maternal deaths in bangladesh by 44% reveals systematic use of torture by US whether those who ordered the use of torture will be held to account."
Leonard Rubenstein, president of Physicians for Human Rights, told the meeting: "Rigorous clinical evaluations confirm the enormous and enduring toll of agony and anguish inflicted for months by US personnel on 11 men who were detained without any charge or explanation."
He explained that the physical and psychological evaluation of the detainees and the documentation of the crimes were based on "internationally accepted standards for clinical assessment of torture claims." A team of two doctors spent two days examining each one of the 11 men and went through the medical records kept by their interrogators.
Dr Rubenstein said, "Their first hand accounts, now confirmed by medical and psychological examinations, take us behind the photographs to write a missing chapter of America's descent into the shameful practice and official policy of systematic torture."
Christian Pross, of the Berlin Centre for the Treatment of Torture Victims, one of the trauma therapists who interviewed the men, told the BMJ he was shocked that such flagrant abuses would be tolerated by a democratic government.
Broken Laws, Broken Lives: Medical Evidence of Torture by US Personnel and its Impact is available at http://physiciansforhumanrights.org.
Nations' millennium development goals to reduce the number of maternal deaths by three quarters between 1990 and 2015, the report adds. The neighbouring countries India and Pakistan are also unlikely to meet this target.
Europe, the Middle East, the American continent, China, Cambodia, and Yemen are likely to achieve the target, although more needs to be done to reach the poorest women in these countries, the report says.
However, most of the world's poorest countries, such as Malawi, are seriously "off track" in reaching the target. Weak health systems, lack of access to family planning, and unsafe abortions are the underlying causes.
Just 2% of worldwide aid currently earmarked for development-what the report describes as "a small fraction of world spending"-would be enough to meet the UN target on maternal mortality.
The United Kingdom will call on leaders of the world's richest countries at the G8 summit in July to commit themselves to plug this gap. It will ask them to invest in health workforces to ensure that by 2015 every country has at least 2.3 health workers per 1000 people, which would enable at least 80% of deliveries to have a skilled attendant present.
The report says that the Department for International Development spent £23.2m (€30m; $45m) on projects around the world to improve maternal and neonatal health in 2007, a 10-fold increase since 2002. This is part of the department's total £800m annual expenditure on health. 
Zosia Kmietowicz London
More patients in the United Kingdom will be offered the chance to take part in research trials and contribute to the improvement of medicine, under new plans announced this week by the government.
Researchers will be able to use electronic patient records to make patients aware of research trials that may be relevant to them, said the health secretary, Alan Johnson, at a research summit to commemorate 60 years of NHS research. Patients will be able to take part if they meet the entry criteria.
"I want every patient in the NHS to have the right to take part in approved medical research that is appropriate to them, if they choose to. And to underline the paramount importance of research we will set out in the forthcoming NHS constitution the core role that it plays at the heart of the NHS," said Mr Johnson.
Gordon Brown, the prime minister, hosted a summit on Tuesday with the UK's top research leaders after meeting staff at the Royal Brompton Hospital in London and officially opening the hospital's new magnetic navigation catheter laboratory.
"As we approach the 60th anniversary of the NHS we have plenty to celebrate," Mr Drug maker's PR firm is force behind blood clot awareness
Ray Moynihan MeLbourne
The international public relations firm Fleishman-Hillard, working with funds from the drug maker SanofiAventis, is helping run a high profile campaign to raise public awareness about blood clots.
The campaign, currently running in Australia under the banner of a coalition of health professionals, has generated headlines claiming that blood clots are more deadly than AIDS and articles suggesting that injections for patients at risk of developing clots may become mandatory.
A national expert on drugs, Alasdair Millar, said that any suggestion that all medical inpatients should receive injections to prevent clots are "extreme and scandalous" and "could cause more harm than good."
Evidence suggests that many hospital patients, whether surgical or medical, could benefit from a greater use of drugs to prevent serious clots, including low molecular weight heparins. But Professor Millar is concerned that these drugs will be given to patients who do not need them, thus exposing them unnecessarily to the risk of bleeding.
Since the launch of the public awareness campaign, media stories have referred to hospital guidelines, a journal article, and a report about the economic costs of serious clots, without disclosing the fact that a key sponsor of all these materials is Sanofi-Aventis. SanofiAventis markets enoxaparin-a low molecular weight heparin used to treat and prevent clots-in Australia.
A spokesperson for FleishmanHillard told the BMJ that it is helping the group of doctors running the campaign with "logistics and the development of materials" and that its work is being funded by SanofiAventis. Fleishman-Hillard is part of the global Omnicom network of advertising and marketing agencies.
Fleishman-Hillard's websites say that the firm can help with "conditioning the market" for a company's drug, can ensure that "product messages reach the right people at the right time," and can facilitate relationships with "thirdparty organisations" such as the coalition fighting blood clots.
Sanofi-Aventis declined to comment, but it has endorsed Fleishman-Hillard as one of its preferred PR agencies.
Sian Davis of Fleishman-Hillard told the BMJ that the coalition wants "assessment and prophylaxis to be standard in hospitals and mandatory." She explained that a three step process had been unfolding in recent months, involving the release of hospital guidelines, the publication of a research study in Lancet, and a summit in Sydney.
The hospital guidelines explicitly endorse expanded use of the drugs, recommending enoxaparin at the top of the list of treatments for high risk medical and surgical patients.
Written by a working party of experts, the current, fourth edition of the guidelines is based on consensus statements from international bodies and is produced and distributed with financial support from a range of companies, including SanofiAventis, a fact that is not disclosed in versions currently being used in some Australian hospitals.
The Lancet study (2008;371:387-94 ) was sponsored by Sanofi-Aventis, which also provided editorial support for the journal article. Eight of the 10 named authors disclosed direct or indirect financial ties to Sanofi-Aventis, and one was an employee of the company.
At the public summit-held in Sydney last month and organised with help from FleishmanHillard-the Coalition for Action on VTE (venous thromboembolism) launched a report estimating that the problem would cause more than 5000 preventable deaths and cost the Australian economy $A1.7bn (£0.8bn; €1bn; $1.6bn) this year. The summit and the report were both partly funded by Sanofi-Aventis; and although the summit sponsors were declared on the day of the summit, sponsors' names were not stated in the report launched at the summit, which was written by Access Economics, an Australian consultancy firm. The fourth international report of the health behaviour in school aged children (HBSC) study, organised by WHO and the University of Edinburgh, provides comprehensive evidence on the health of young people in industrialised nations.
It highlights concerns about underage drinking in Britain. Wales was worst of all the 41 countries for the number of 13 year olds who reported being drunk twice or more; Scotland was second and England fourth. High rates of underage drinking were also found in Denmark and the Baltic states.
In England and Wales more than two thirds of 15 year olds reported feeling under pressure in school, one of the highest recorded rates. British children also found it harder than most to talk to their parents but were among the most sociable, ranking highly for the number who had three or more close friends. There were also positive findings for the UK in the amount of fruit consumed by 11 year olds, and fewer children were now drinking sugary soft drinks, the report said.
Canada and the United States had the lowest prevalence of cigarette smoking among children but the highest prevalence of cannabis use. Canada, Greenland, Malta, and the US had among the highest percentages of overweight young people.
The report shows that positive health behaviours, such as daily fruit consumption and regular physical activity, are most likely at age 11 but then decline. Confirming that Sanofi-Aventis was one of the sponsors of the report, the director of Access Economics, Lynne Pezzullo, said that no sponsor had any part in the report's direction or findings. "Pharmaceutical companies don't make atomic weapons," she said. "They make medicines that continue to improve our health and wellbeing."
The chairman of the doctors' working party that wrote the guidelines, commissioned the economic report, and initiated the coalition and summit is John Fletcher, professor of surgery at the University of Sydney. Arguing that expanded use of appropriate prophylaxis could reduce the number of deaths from venous thromboembolism, Professor Fletcher also cautioned that drugs should not be targeted at patients who are at low risk of developing blood clots.
Asked whether sponsors' names should be stated in sponsored materials such as the hospital guidelines and the report written by Access Economics, Professor Fletcher 
